Compositions, devices, and methods for the treatment of overdose and reward-based disorders
AssigneesAegis Therapeutics, LLC, Opiant Pharmaceuticals, Inc.
InventorsEdward T. Maggio, Roger Crystal, Mark Ellison, Phil Skolnick
Life of this patent
Estimating the term…
Abstract
Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.
Claims28
An intranasal formulation comprising an aqueous solution comprising between about 1 mg and about 4 mg naltrexone, or a pharmaceutically acceptable salt thereof.
An intranasal formulation comprising, in a volume of about 50 to about 150 μL, an aqueous solution comprising between about 10 mg/mL and about 40 mg/mL naltrexone, or a pharmaceutically acceptable salt thereof.
A method of treatment of opioid overdose or a reward-based disorder in a subject, comprising administering to the subject an intranasal formulation comprising an aqueous solution comprising between about 1 mg and about 3 mg naltrexone or a pharmaceutically acceptable salt thereof.
A method of treatment of opioid overdose or a reward-based disorder in a subject, comprising administering to the subject a first intranasal formulation comprising an aqueous solution comprising between about 1 mg and about 4 mg naltrexone or a pharmaceutically acceptable salt thereof and administrating a second intranasal formulation comprising an aqueous solution comprising between about 1 mg and about 4 mg naltrexone or a pharmaceutically acceptable salt thereof.
A method of treatment of opioid overdose or a reward-based disorder in a subject, comprising administering to the subject an intranasal formulation comprising, in a volume of about 50 to about 150 μL, an aqueous solution comprising between about 10 mg/mL and about 30 mg/mL naltrexone or a pharmaceutically acceptable salt thereof.
A method treatment of opioid overdose or a reward-based disorder in a subject, comprising administering to the subject a first intranasal formulation comprising, in a volume of about 50 to about 250 ul, an aqueous solution comprising between about 10 mg/mL and about 40 mg/mL naltrexone or a pharmaceutically acceptable salt thereof and administrating a second intranasal formulation comprising, in a volume or about 50 to about 250 μL, an aqueous solution comprising between about 10 mg/mL and about 40 mg/mL naltrexone or a pharmaceutically acceptable salt thereof.
28-66. (canceled)
Dependencies are inferred from the claim text.